Combined platelet and red blood cell recovery during on-pump cardiac surgery using same™ by i-SEP autotransfusion device: a first-in-human non-comparative study (i-TRANSEP study) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Anesthesiology Année : 2023

Combined platelet and red blood cell recovery during on-pump cardiac surgery using same™ by i-SEP autotransfusion device: a first-in-human non-comparative study (i-TRANSEP study)

Diane Zlotnik
  • Fonction : Auteur
Elodie Boissier

Résumé

Background - Centrifugation-based autotransfusion devices only salvage red blood cells while platelets are removed. The same™ device (Smart Autotransfusion for ME; i-SEP, France) is an innovative filtration-based autotransfusion device able to salvage both red blood cells and platelets. The authors tested the hypothesis that this new device could allow a red blood cell recovery exceeding 80% with a posttreatment hematocrit exceeding 40%, and would remove more than 90% of heparin and 75% of free hemoglobin. Methods - Adults undergoing on-pump elective cardiac surgery were included in a noncomparative multicenter trial. The device was used intraoperatively to treat shed and residual cardiopulmonary bypass blood. The primary outcome was a composite of cell recovery performance, assessed in the device by red blood cell recovery and posttreatment hematocrit, and of biologic safety assessed in the device by the washout of heparin and free hemoglobin expressed as removal ratios. Secondary outcomes included platelet recovery and function and adverse events (clinical and device-related adverse events) up to 30 days after surgery. Results - The study included 50 patients, of whom 18 (35%) underwent isolated coronary artery bypass graft, 26 (52%) valve surgery, and 6 (12%) aortic root surgery. The median red blood cell recovery per cycle was 86.1% (25th percentile to 75th percentile interquartile range, 80.8 to 91.6) with posttreatment hematocrit of 41.8% (39.7 to 44.2). Removal ratios for heparin and free hemoglobin were 98.9% (98.2 to 99.7) and 94.6% (92.7 to 96.6), respectively. No adverse device effect was reported. Median platelet recovery was 52.4% (44.2 to 60.1), with a posttreatment concentration of 116 (93 to 146) · 109/l. Platelet activation state and function, evaluated by flow cytometry, were found to be unaltered by the device. Conclusions - In this first-in-human study, the same™ device was able to simultaneously recover and wash both platelets and red blood cells. Compared with preclinical evaluations, the device achieved a higher platelet recovery of 52% with minimal platelet activation while maintaining platelet ability to be activated in vitro.

Dates et versions

hal-04165094 , version 1 (18-07-2023)

Identifiants

Citer

Alexandre Mansour, Antoine Beurton, Anne Godier, Bertrand Rozec, Diane Zlotnik, et al.. Combined platelet and red blood cell recovery during on-pump cardiac surgery using same™ by i-SEP autotransfusion device: a first-in-human non-comparative study (i-TRANSEP study). Anesthesiology, 2023, 139 (3), pp.287-297. ⟨10.1097/ALN.0000000000004642⟩. ⟨hal-04165094⟩
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More